CA-15-3 BioAssay(TM) ELISA Kit

Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are node-negative, however 30% of these cases progress to metastatic disease. There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly metastatic diseases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 are more sensitive than CEA in early detection of breast cancer recurrence. In combination with CA-125, CA15-3 has been shown to be useful in early detection of relapse of ovarian cancer. CA15-3 levels are also increased in colon, lung and hepatic tumors.\n\nDetection Range: 0-200U/ml\n\nSpecificity: 97%\n\nSensitivity: 5units/ml\n\nKit Components: \nMicrotiter Plate, 1x96wells\nSample DIluent, 1x100ml\nEnzyme Conjugate Reagent, 1x22ml\nStandard 0unit/ml, 1x1vial\nStandard 15unit/ml, 1x1vial\nStandard 30unit/ml, 1x1vial\nStandard 60unit/ml, 1x1vial\nStandard 120unit/ml, 1x1vial\nStandard 240unit/ml, 1x1vial\nTMB Substrate, 1x12ml\nStop Solution, 1x12ml\nWash Buffer Concentrate (50X), 1x15ml\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

167547

Size

96Tests

Applications

ELISA

References

1. Aziz DC, Rittenhouse HJ, Ranken R. Use and interpretation of tests in oncology. Santa Monica: Specialty Laboratories, 1991. 2. Aziz DC. A J Clin Pathol 1992;98:105-11 3. Aziz DC, J Clin Pathol 1991;5:422-38. 4. Clark GM, Dressler LG, Owens MA, Dounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33. 5. Elledge RM, McGuire WL. Annu Rev Med 1993;44:201-10. 6. Foekens JA, et al., Cancer Res 1990; 50-3832-7. 7. Isola J, J Cell Biochem 1992;(Suppl 16D):101. 8. Kute TE, et al., ancer Res 1992;52- 198-203. 9.McGuire WL, Tandon AK, Allred D, Chamnes GC, Clark GM. How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-7. 10. Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr): results of a 6 year follow up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 1991;63:146- 50. 11. Somerville JE, Clarke LA, Biggart JD. C-erb B-2 overexpression and histological type of in-situ and invasive breast carcinoma. J Clin Pathol 1992;45-16-20. 12. Ueronese S, Gambacorta M. Detection of Ki-67 rate in breast cancer. Am J Clin Pathol 1991;95:30-4. 13. Lotnicker M, Pavesi F, Scarabelli M. Tumor associated antigens CA15-3 and CA-125 in ovarian cancer. Int. J.\nBiolog Markers 1991; 6:115